


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |   |   |
|--|---|---|
| (51) International Patent Classification 6 :<br>C07J 41/00, 51/00, 21/00, 7/00, 71/00  | A2  | (11) International Publication Number: WO 96/3035<br>(43) International Publication Date: 3 October 1996 (03.10.) |
| (21) International Application Number: PCT/US96/03660<br>(22) International Filing Date: 18 March 1996 (18.03.96)<br>(30) Priority Data:<br>08/413,755            30 March 1995 (30.03.95)            US<br>(71) Applicant: THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health [US/US]; Office of Technology Transfer, Box OTT, Bethesda, MD 20892-9902 (US).<br>(72) Inventors: KIM, Hyun, K.; 6308 Marywood Road, Bethesda, MD 20817 (US). RAO, Pemmaraju, Narasinha; 4307 North Westberry Drive, San Antonio, TX 78228 (US). BURDETT, James, E., Jr.; 10790 South FM2790W No. 4, Somerset, TX 78069 (US). ACOSTA, Carmie, Kirk; 12430 Autumn Vista, San Antonio, TX 78249 (US).<br>(74) Agents: KILYK, John, Jr. et al.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US). | (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AR, patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GN, ML, MR, NE, SN, TD, TG).<br><br>Published<br>Without international search report and to be republished upon receipt of that report. |   |

(54) Title: METHOD FOR PREPARING 17 $\alpha$ -ACETOXY-11 $\beta$ -(4,N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES.



(I)

## (57) Abstract

Methods for the preparation of the 19-norprogesterone of formula (I) and its intermediates, in crystalline and amorphous forms.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AM | Armenia                  | GB | United Kingdom                        | MW | Malawi                   |
| AT | Austria                  | GE | Georgia                               | MX | Mexico                   |
| AU | Australia                | GN | Guinea                                | NE | Niger                    |
| BB | Barbados                 | GR | Greece                                | NL | Netherlands              |
| BE | Belgium                  | HU | Hungary                               | NO | Norway                   |
| BF | Burkina Faso             | IE | Ireland                               | NZ | New Zealand              |
| BG | Bulgaria                 | IT | Italy                                 | PL | Poland                   |
| BJ | Benin                    | JP | Japan                                 | PT | Portugal                 |
| BR | Brazil                   | KE | Kenya                                 | RO | Romania                  |
| BY | Belarus                  | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CA | Canada                   | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CF | Central African Republic | KR | Republic of Korea                     | SE | Sweden                   |
| CG | Congo                    | KZ | Kazakhstan                            | SG | Singapore                |
| CH | Switzerland              | LI | Liechtenstein                         | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LK | Sri Lanka                             | SK | Slovakia                 |
| CM | Cameroon                 | LR | Liberia                               | SN | Senegal                  |
| CN | China                    | LT | Lithuania                             | SZ | Swaziland                |
| CS | Czechoslovakia           | LU | Luxembourg                            | TD | Chad                     |
| CZ | Czech Republic           | LV | Latvia                                | TG | Togo                     |
| DE | Germany                  | MC | Monaco                                | TJ | Tajikistan               |
| DK | Denmark                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| EE | Estonia                  | MG | Madagascar                            | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                  | UG | Uganda                   |
| FI | Finland                  | MN | Mongolia                              | US | United States of America |
| FR | France                   | MR | Mauritania                            | UZ | Uzbekistan               |
| GA | Gabon                    |    |                                       | VN | Viet Nam                 |


**METHOD FOR PREPARING 17 $\alpha$ -ACETOXY-11 $\beta$ -(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE METHOD, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES**

**TECHNICAL FIELD OF THE INVENTION**

The present invention relates generally to steroids and, in particular, to methods for the preparation of 17 $\alpha$ -acetoxy-11 $\beta$ -(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates useful in those methods, and methods for the preparation of such intermediates.

**BACKGROUND OF THE INVENTION**

The compound 17 $\alpha$ -acetoxy-11 $\beta$ -(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, represented by formula I



(I),

is a well-known steroid, more specifically a 19-norprogesterone, which possesses antiprogestational and antiglucocorticoidal activity. This compound, and a method for its preparation, are described in U.S. Patent 4,954,490.

The method for the preparation of the 19-norprogesterone compound of formula I set forth in the '490 patent is reproduced in Figure 1. This method begins by converting 3-methoxyesterone 1 to a tetra-ene 2 via the Wittig reaction using ethyl triphenyl phosphonium

iodide. The tetra-ene 2 is then hydroxylated using  $\text{OsO}_4$  to provide the compound of formula 3. That compound is then reduced using  $\text{Li/NH}_3$  to form compound 4, with the latter being subjected to mild acid hydrolysis to form compound 5. Subsequently, compound 5 is subjected to bromination-dehydrobromination to provide a dienone 6. Swern oxidation is then used to convert the dienone 6 to compound 7, with compound 7 being ketalized to provide a ketal 8. The ketal 8 is then epoxidized using m-chloroperbenzoic acid to provide an epoxide 9. The epoxide then undergoes conjugate ring-opening using a copper (I) catalyzed Grignard reagent generated by the reaction of 4-bromo-N,N dimethylaniline with magnesium in the presence of copper (I) to provide compound 10. A single-step hydrolysis/acetylation/dehydration procedure, using  $\text{H}_3\text{PO}_4/\text{Ac}_2\text{O}/\text{HOAc}$ , is then used to convert compound 10 to the desired 19-norprogesterone of formula I (indicated as compound 11 in Figure 1).

While the foregoing procedure can be used to provide the 19-norprogesterone of formula I, certain drawbacks are inherent therein. More specifically, the foregoing procedure includes processing steps which are hazardous and/or not readily amenable to the preparation of relatively large quantities of the desired 19-norprogesterone, e.g., the use of highly toxic and expensive  $\text{OsO}_4$  to effect hydroxylation, effecting Birch reduction using lithium and ammonia, as well as bromination-dehydrobromination and Swern oxidation procedures. Moreover, many of the steps require chromatographic purification for the isolation of the intermediates. Further, the overall yield provided by this known process is relatively low.


In view of the foregoing, a need exists for a relatively safer and more efficient process for the preparation of the 19-norprogesterone of formula I and intermediates thereof, which process is further able to provide those compounds in relatively high quantities

and purity levels, as compared to known methods. These and other objects and advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.

#### BRIEF SUMMARY OF THE INVENTION


One aspect of the present invention provides methods for the preparation of the 19-norprogesterone of formula I and its intermediates which are relatively safer and more efficient, and which further provide those compounds in relatively high quantities and purity levels, as compared to known methods.

With respect to the preparation of the 19-norprogesterone of formula I, the present invention comprises protecting the hydroxyl group in the compound of formula II




(II)

with a protecting group B, which protecting group comprises a halomethyl functional group, to provide the compound of formula III




(III),

- reacting the protected compound of formula III with an alkali or alkaline earth metal anion radical comprised of an alkali or alkaline earth metal and an anion radical and hydrolyzing the resulting compound to provide the compound of formula IV




(IV),

- 10 ketalizing the carbonyl groups of the compound of formula IV to provide the compound of formula V



(V),

- 15 epoxidizing the compound of formula V to provide the 5 $\alpha$ ,10 $\beta$ -epoxide compound of formula VI




(VI),

20


- opening the epoxide ring in the compound of formula VI and substituting a N,N-dimethylaminophenyl functional

group in the axial position of C<sub>11</sub> to provide the compound of formula VII



(VII),

deketalizing and dehydrating the compound of formula VII to provide the compound of formula VIII



(VIII),

and acetylating the compound of formula VIII to provide the compound of formula I.


By following the foregoing method, one is able to avoid using the hazardous bromination-debromination and Swern oxidation procedures and, further, is able to obtain the desired 19-norprogesterone in a relatively high yield and purity level.

As mentioned previously, another aspect of the present invention provides methods for the preparation of several of the intermediates useful in the foregoing method for the preparation of the 19-norprogesterone of formula I.

Yet another aspect of the present invention provides crystalline forms of the 19-norprogesterone of formula I, as well as certain of the aforesaid intermediates, i.e., the compounds of formulas V, VI,

6

VII, and VIII, as well as of IIIa (which is formula III in which B is  $-\text{Si}(\text{CH}_3)_2\text{CH}_2\text{Cl}$ )



5

#### DESCRIPTION OF THE DRAWINGS

Figure 1 sets forth the method for the preparation of the 19-norprogesterone of formula I (indicated in this figure as the compound of formula 11) as described in U.S. Patent 4,954,490.

Figure 2 sets forth the method for the preparation of the 19-norprogesterone of formula I in accordance with the present invention.


15

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention may best be understood with reference to the following detailed description of the preferred embodiments.

20


One aspect of the present invention provides a method for preparing the compound of formula I



25

Prior to initiating the inventive method, the starting material, i.e., the compound of formula II






(II)

must be obtained. This compound is commercially  
 5 available from Roussel-Uclaf (Paris, France).

As an initial step, the hydroxyl group in the  
 compound of formula II is protected by the addition of a  
 protective group to form the compound of formula III



(III).

While any suitable protecting group having a halomethyl  
 functional group may be utilized, it has been  
 15 advantageously found that a silane radical  
 ( $-\text{Si}(\text{CH}_3)_2\text{CH}_2\text{X}$ , wherein X is Cl, Br or I), and preferably  
 (because it is the least costly of the three radicals)  
 the radical formed from chloromethyldimethylchlorosilane  
 (i.e.,  $-\text{Si}(\text{CH}_3)_2\text{CH}_2\text{Cl}$ ), provides certain benefits, e.g.,  
 20 each may be readily generated from commercially  
 available materials.

When the preferred protecting group is used, the  
 reaction preferably proceeds by reacting the compound of  
 formula II with that protecting group in a suitable  
 25 anhydrous solvent. Examples of solvents suitable for  
 this reaction include, but are not limited to,  
 tetrahydrofuran (THF), diethyl ether, acetonitrile,

dichloromethane, dioxane, and the like, with THF being a preferred solvent.

The protecting reaction is preferably further conducted in the presence of a base, the base  
5 functioning to scavenge the acid by-product. Examples of suitable bases include triethylamine and pyridine.


Most preferably, the protecting reaction is further conducted in the presence of a silylation catalyst, e.g., 4-N,N-dimethylaminopyridine (DMAP), which is  
10 typically present in a substoichiometric amount.

During the reaction, the reactants are advantageously maintained at a temperature of from about 0°C to about 40°C, and preferably at a temperature of about 25°C. When the reaction is complete, the  
15 reaction mixture is diluted with a non-polar solvent or mixture of such solvents, e.g., pentanes and hexanes, to precipitate the amine hydrochloride byproduct. The precipitate may then be removed by any known method, e.g., filtration. The filtrate may then be concentrated  
20 by evaporation, and subsequently diluted with a solvent, e.g., diethyl ether, in order to be able to subject it to further purification. It is preferred that the solution be kept under a dry atmosphere, such as a nitrogen atmosphere. The solution is then preferably  
25 passed through a silica gel column to obtain the compound of formula IIIa (assuming the protecting group is  $-\text{Si}(\text{CH}_3)_2\text{CH}_2\text{Cl}$ ) as a crystal (m.p. 80° to 82°C) in 98% yield.

The protected compound of formula III is then  
30 reacted in a single-step with an alkali or alkaline earth metal anion radical comprised of an alkali or alkaline earth metal and a radical anion. It is believed that, during the reaction, the nucleophilic carbon atom of the halomethyl functional group in the  
35 protecting group intramolecularly attacks the nitril group and forms a cyclic structure thereof.  
Therefore, selection of the alkali or alkaline earth

metal anion radical should be based upon the ability of the radical to initiate the aforementioned intramolecular attack. Examples of suitable alkali metals that can be used in the practice of the present invention include lithium, sodium, potassium, and rubidium, with lithium being preferred. Calcium is a preferred alkaline earth metal. Examples of compounds suitable for forming the radical anion include naphthalene, di-tert-butyl naphthalene, di-tert-butylbiphenyl (DBB), anthracene, naphthacene, benzanthrene, benzophenone, 1,3,5-trinitrobenzene, dimethylaminonaphthalene, diisopropylamide, hexamethyl phosphoric triamide, ammonia, and 18-crown-6. The use of DBB is preferred in view of its high efficiency in generating the anion radical. See Freeman et al., *J. Org. Chem.* 45, 1924-1930 (1980).

The resulting reaction mixture, which includes the aforescribed compound having the two cyclic structures, i.e., the cyclic ketal group and the cyclic structure formed by the previously described intramolecular attack, is then quenched with an excess of acid, advantageously an aqueous acid, and the compound having the said two cyclic structures is concomitantly hydrolyzed, to provide the compound of formula IV



(IV).


Preferably, the aforesaid resulting reaction mixture is quenched with  $\text{CH}_2\text{Cl}_2$  to destroy any excess alkali metal or alkaline metal anion radical present in that mixture prior to the acid quenching step.

When the preferred compound is used in the foregoing reaction sequence, i.e., DBB, the reaction of the alkali metal with DBB is preferably conducted in the presence of a solvent, e.g., THF. As the alkali metal/DBB complex is highly sensitive to oxygen and moisture, care should be exercised in handling this complex. Subsequently, the alkali metal/DBB complex is reacted with the compound of formula III.

The reactants should advantageously be contacted with one another at a low temperature, preferably at about  $-75^{\circ}\text{C}$  to about  $-30^{\circ}\text{C}$ , due to the instability of the reaction intermediates.

When the protecting group is the radical  $-\text{Si}(\text{CH}_3)_2\text{CH}_2\text{X}$  (as described previously), this building of the pregnane side chain is advantageously completed using a single-step procedure known as the Silicon Nucleophilic Annealation Process (SNAP). See Livingston et al., *Adv. Med. Chem.* **1**, 137-174 (1992); Livingston et al., *J. Am. Chem. Soc.* **112**, 6449-6450 (1990); U.S. Patent 4,921,638; and U.S. Patent 4,977,255. When SNAP is utilized, the compound of formula III (wherein B is  $-\text{Si}(\text{CH}_3)_2\text{CH}_2\text{X}$ , wherein X is preferably Cl) is reacted with the DBB anion radical generated from DBB and the alkali metal (e.g., lithium) in a solvent, e.g., THF. This results in the formation of an  $\alpha$ -silyl carbanion, which attacks the nitrile intramolecularly to provide an intermediate silacycle. Subsequent acid hydrolysis of this intermediate provides the  $17\alpha$ -hydroxy-20-ketone moiety, and concomitant deketalization provides the compound of formula IV.

After the compound of formula IV is prepared, the carbonyl groups of that compound are ketalized to provide the compound of formula V



(V).

5 The ketalization step may be conducted in any suitable manner, but is preferably undertaken by reacting the compound of formula IV with a diol in the presence of an acid.


10 Any suitable acid may be used in the foregoing reaction, as long as it functions to catalyze the formation of the ketal. Suitable acids for this purpose include sulfur-based organic acids, e.g., methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid, with toluenesulfonic acid being preferred.

15 Any suitable diol may be used in the reaction, provided that it is able to provide a cyclic ketal. Such diol should further be provided in excess with respect to the carbonyl groups being ketalized, such so as to favor the formation of the cyclic ketal. A preferred diol for this reaction is ethylene glycol.

20 Various orthoesters are suitable for use in the foregoing reaction, the orthoesters functioning to chemically remove the water from the reaction and drive the reaction to completion. Orthoformate esters are advantageously utilized because they provide high yields. Preferred orthoformate esters include triisobutyl orthoformate and triisopropyl orthoformate, with triethyl orthoformate being most preferred.

25 The compound of formula V is then epoxidized to form the 9,11-unsaturated 5α,10β-epoxide of formula VI

30



(VI).

5 This reaction is advantageously accomplished by reacting the compound of formula V with an adduct formed from the reaction of a halogenated acetone and a peroxide in the presence of an inorganic phosphate. Any suitable peroxide, or peracid, may be used in this reaction. Examples of suitable peroxides include hydrogen

10 peroxide, sodium peroxide, potassium peroxide, benzoyl peroxide, and acetyl peroxide, with the preferred peroxide being 30 wt.% hydrogen peroxide in water.

The halogenated acetone may comprise any such acetone which provides the desired results.

15 Advantageously, a hexahalogenated acetone is used, e.g., hexafluoroacetone, hexachloroacetone and hexabromoacetone, with hexafluoroacetone being preferred. Such hexahalogenated acetones provide the 5α,10β-epoxide in the greatest yield.

20 The reaction is preferably carried out in the presence of an inorganic base. Examples of suitable bases include di- and tri-basic sodium and potassium phosphate, sodium and potassium carbonate, and sodium and potassium bicarbonate, with dibasic sodium phosphate being preferred. Especially preferred is the use of

25 dibasic sodium phosphate in combination with the 30 wt.% hydrogen peroxide and hexafluor acetone .


Th e reaction is further advantageously conducted in the presence f a solvent. The solvent should

30 advantageously be a halogenated solvent. Suitable solvents include chloroform, methylene chloride,

dichloroethane, and trichloroethane, with a preferred solvent being methylene chloride.

The compound of formula VI can be crystallized (m.p. 188.5°C to 191.5°C) using an ether, e.g., diethyl ether, isopropyl ether, isobutyl ether, and n-butyl ether, with diethyl ether being preferred.

After forming the cyclic ketal protecting groups, the epoxide in the compound of formula VI, advantageously in its crystalline form, undergoes a conjugate ring-opening reaction, and a N,N-dimethylaminophenyl functional group may be substituted in the axial position of C<sub>11</sub>, to provide the compound of formula VII



(VII).

The foregoing reaction is advantageously completed by reacting the crystalline compound of formula VI with a Grignard reagent prepared from the reaction of p-bromo-N,N-dimethylaniline and magnesium in the presence of a cuprous halide.

It was surprisingly discovered that, when this reaction scheme was undertaken, less Grignard reagent was required as compared to the amount of such agent required in the conversion of the unpurified product. More specifically, the reaction may be carried out with about a five-fold excess of Grignard reagent over the epoxide as opposed to the nearly eight-fold excess used in the process described in the '490 patent.


The crystalline form of compound VI further permits the use of a relatively small amount of the cuprous

halid reagent. More specifically, the conjugate ring opening reaction of the  $5\alpha,10\beta$ -epoxide can be carried with the molar ratio of the cuprous halide to the  $5\alpha,10\beta$ -epoxide at about one-half; this being contrasted with the more than equimolar quantity of cuprous reagent described in the '490 patent.

It was further surprisingly discovered that the use of the crystalline form of compound VI, while using a relatively small amount of reagents (e.g., Grignard and cuprous halide), provided the compound of formula VII in high yield and purity, without requiring purification to be undertaken by means of time-consuming chromatographic methods.

Compound VII is further advantageously obtained in crystalline form (m.p.  $236^{\circ}\text{C}$  to  $240^{\circ}\text{C}$ ) by crystallization from an ether, preferably, diethyl ether.

The compound of formula VII, advantageously in its crystalline form, is then deketalized and dehydrated to provide the compound of formula VIII



(VIII),

wherein thereafter the compound of formula VIII is acetylated to provide the compound of formula I.

The foregoing conversion of the compound of formula VII to the compound of formula I is completed by carrying out the conversion in two steps. This two-step procedure is in direct contrast to the one-step procedure described in the '490 patent. More specifically, the first step comprises the conversion of the compound of formula VII to the compound of formula



VIII by reaction with a dilute alcoholic acid solution. The acid serves the dual function of hydrolyzing the ketal group (i.e., deketalization) and removing the hydroxyl at C<sub>5</sub> position (i.e., dehydration). Any acid  
5 which functions to hydrolyze the ketal group is suitable for use, including sulfuric acid, hydrochloric acid, and phosphoric acid.

After its formation, the compound of formula VIII may be crystallized (m.p.: softens at 103°C and foams at  
10 125°C to 128°C) from ether in high yield and in high purity. The compound of formula I may then be prepared from the compound of formula VIII, advantageously its crystalline form, by acetylation. Although any suitable reactants may be utilized to complete the acetylation,  
15 advantageously, a mixed anhydride procedure employing a trifluoroacetic anhydride/acetic acid mixture is used. This procedure has been found to provide the compound of formula I in high purity and yield from the compound of formula VIII without resort to chromatography. After  
20 its formation, the compound of formula I can be purified by crystallization from ether in high yield and high purity (m.p.: 183°C to 185°C).

The inventive method for preparing the compound of formula I from the compound of formula VII in two steps  
25 was surprisingly found to provide a greater yield of the desired product than the one step method described in the '490 patent, i.e., a net yield of about 68% as compared to about 16% as calculated from the yields reported in the '490 patent.

30 From an overall perspective, the inventive method provides a much greater yield of the final product of formula I as compared to that provided by the '490 patent, and also avoids many of the problems of the reaction scheme described in the '490 patent, such as  
35 the use of synthetic procedures which are unreasonably hazardous and/or not readily amenable to scale-up. By following the methods of the present invention, one may

obtain an overall yield of the compound of formula I of about 12% starting from compound II. This is contrasted with the nine-step method described in the '490 patent which provides an overall yield of about 0.65% as  
5 calculated from the reported yields at the various steps. A preferred embodiment of the present inventive reaction scheme is depicted in Figure 2.

The instant invention further allows one to prepare any of the intermediates described herein starting from  
10 the compound of formula II, or any other preceding intermediate, as well as the compound of formula I starting from any of the aforesaid.

The following examples further illustrate the present invention but, of course, should not be  
15 construed as in any way limiting its scope.

#### EXAMPLE 1

The Preparation of the Compound of Formula (IIIa)  
20 (3-ethylenedioxy-17 $\beta$ -cyano-17 $\alpha$ -chloromethyl-(dimethyl)silyloxyestra-5(10),9(11)-diene) from the Compound of Formula (II)

700 grams (2.05 mol) of the cyanohydrin-ketal (II)  
25 were suspended in about 5,000 mL of anhydrous THF. 58 grams (0.47 mol) of 4-N,N-dimethylaminopyridine were added while maintaining vigorous stirring, followed by the addition of 335 mL (2.40 mol) of triethylamine. 300 mL (2.25 mol) of chloro(chloromethyl)dimethylsilane were  
30 added over 15 minutes to the mixture. After stirring for 15 hours at room temperature, the mixture was diluted with 5,000 mL of hexanes and stirred for 10 minutes. The mixture was filtered through a pad of Celite. The filtrate was evaporated, and the residue  
35 was taken up in 2,500 mL of ether. This ether solution was percolated under nitrogen through a (15 x 20 cm) column of pre-equilibrated silica gel (flash column grade) contained in a large flash column (15 x 70 cm). Evaporation of the ether solution from the column gave

898 g of white crystalline powder (i.e., the compound of formula (IIIa)) in 98% yield; m.p. 80-82°C. The material was found to be homogeneous by Thin Layer Chromatography (TLC) (30% EtOAc/Hex) and was used in the next reaction without further purification. FTIR (KBr, diffuse reflectance):  $\gamma_{\max}$  3034, 2977, 2947, 2865, 2230 (CN), 1546, 1473, 1431, 1383, 1346, 1322, 1256 & 1235 (O-CH<sub>2</sub>CH<sub>2</sub>-O), 1173, 1158, 1131 (Si-O-CH<sub>2</sub>), 1099, 1058, 1041, 1010 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  0.47 (s, OSi(CH<sub>3</sub>)<sub>2</sub>), 0.90 (s, 18-CH<sub>3</sub>), 2.88 (s, OSiCH<sub>2</sub>Cl), 3.99 (br. s, 3-O(CH<sub>2</sub>)<sub>2</sub>O-), 5.60 (br. s, C-11 H); MS (EI): m/z (relative intensity) 448(M<sup>+</sup>, 33), 447(M<sup>+</sup>-H, 100), 419(43), 374 (33), 323 (26), 308 (43), 295 (40), 280 (34), 250 (29), 236 (48), 222 (26), 169 (39), 155 (30), 129 (27), 99 (54), 91 (31), 86 (84), 79 (34), 75 (30).

## EXAMPLE 2

The Preparation of the Compound of Formula (IV), (17 $\alpha$ -Hydroxy-19-norpregna-4,9-diene-3,20-dione) From The Compound of Formula (IIIa)

300 grams of a 30% by weight dispersion of lithium metal in mineral oil (12.97 mol of Li) were placed in a 2.0 L addition funnel under argon. 759 mL of pentane were added to the addition funnel, and the lithium metal was allowed to migrate to the top. The lower pentane-mineral oil layer was carefully drained into a large flask. The addition funnel was fitted onto a 12.0 L, 3 neck reaction flask. The lithium metal was washed into the flask with 1,300 mL of THF. The flask was fitted with a stirring shaft having a glass paddle. 1,300 mL of a THF solution containing 500 g (1.88 mol) of di-*t*-butylbiphenyl (DBB) were added to the THF suspension of lithium using a metering pump. The resulting blue Li/DBB mixture was stirred at room temperature for 2 hours. After chilling the flask to -70°C, 2,400 mL of a THF solution containing 898 g of the compound of formula (IIIa) were added to the Li/DBB mixture at a rate

designed to maintain the blue color throughout the addition. Upon completion of the addition, dichloroethane (400 mL) was added slowly to destroy excess anion-radical. 4,000 mL of 6 N aqueous HCl were then added slowly, and the reaction mixture was allowed to warm to room temperature and was stirred overnight.

The reaction mixture was evaporated in vacuo to remove the THF, and the resulting aqueous mixture was extracted with methylene chloride. Following washes with water and brine, the methylene chloride extracts were combined and dried over sodium sulfate. Evaporation of the solvent gave a solid.

The solid was partitioned between hexanes and 90% methanol (3 x 2500 mL Hex/ 3 x 2500 mL, 90% MeOH). The combined methanol layers were evaporated to remove the methanol, and the aqueous mixture was extracted with methylene chloride.

The methylene chloride extracts were washed with water and brine, combined, and dried over sodium sulfate. Evaporation of the solvent gave 572 g of a diketone, i.e., the compound of formula (IV) in 91% yield. The diketone of formula (IV) was a 4:1 mixture of 4,9(10)- and 5(10),9(11)-dienedione. The mixture was converted, without purification, to the 3,20-diketal (i.e., the compound of formula (V)) as described in Example 3. Evaporation of the hexane extracts allowed for the recovery of the DBB. NMR (CDCl<sub>3</sub>)  $\delta$  0.83 (s, 18-CH<sub>3</sub>), 2.30 (s, 21-CH<sub>3</sub>), 5.70 (br.s, C-4 H).

### EXAMPLE 3

The Preparation of the Compound of Formula (V) (3,20-bis-Ethylenedioxy-17 $\alpha$ -hydroxy-19-norpregna-5(10),9(11)-diene) From the Compound of Formula (IV)

To 3,800 mL of a methylene chloride solution containing 543 g of the diketone of formula (IV) (1.73 mol) were added 540 mL of ethylene glycol (9.68 mol), 864 mL of distilled triethyl orthoformate (5.19 mol),

and 21.6 g of p-toluenesulfonic acid monohydrate (0.11 mol). The mixture was stirred overnight at room temperature.

5 The mixture was diluted with 2,150 mL of saturated sodium bicarbonate solution and stirred for 10 minutes. The methylene chloride layer was washed with water (2x) and brine. The aqueous washes were extracted with additional methylene chloride. The methylene chloride extracts were combined and dried over sodium sulfate.

10 The methylene chloride solution was concentrated to a thick syrup. Approximately 2,000 mL of methanol containing 0.5 vol% pyridine was drawn into the evaporation flask and the evaporative removal of the methylene chloride was continued. The flask was removed

15 from the roto-vap, and additional methanol with 0.5 vol% pyridine was added. The flask was chilled to 4°C. The solid obtained was collected by filtration, washed with cold methanol, and dried in vacuo overnight to give 432.5 g of the compound of formula (V) in 62% yield;

20 m.p. 170-172°C. NMR (CDCl<sub>3</sub>)  $\delta$  0.80 (s, 18-CH<sub>3</sub>), 1.38 (s, 21-CH<sub>3</sub>), 4.0 (m, 3,20-diketal), 5.60 (br.s, C-11 H). Anal. Cal'd for C<sub>24</sub>H<sub>34</sub>O<sub>5</sub>: C, 71.61, H, 8.51 Found C, 71.53, H, 8.50.

25

## EXAMPLE 4

The Preparation of the Compound of Formula (VI)  
(3,20-bis-Ethylenedioxy-17 $\alpha$ -hydroxy-5 $\alpha$ ,10 $\beta$ -epoxy-19-norpreg-9(11)-ene) From the Compound of Formula (V)

30

A mixture of 261.5 g of hexafluoroacetone trihydrate (1.18 mol) in 2,500 mL of methylene chloride was chilled to 4°C. To this mixture were added 125 g of sodium phosphat dibasic (0.88 mol) and 238 mL of 30% hydrogen peroxide (210 mmol), and the mixture was

35 stirred for 20 minutes at 4°C. 2,500 mL of a cold (4°C) solution of methylene chloride containing 432.2 g of the diketal of formula (V) (1.08 mol) wer added to the above mixture and stirred overnight at 4°C. The mixture

was diluted with 3,000 mL of a 10 weight % sodium sulfite solution and stirred for 30 minutes. The layers were separated and the aqueous layer was extracted with additional methylene chloride. The methylene chloride  
5 extracts were washed with water and brine, combined, and dried over sodium sulfate. The solvent was evaporated, and the residue was taken up in 1,200 mL of ether. The ether solution was chilled to 4°C, and the resulting solid was collected by filtration, washed with ether,  
10 and dried in vacuo to give 176.8 g of pure 9,11-unsaturated 5 $\alpha$ ,10 $\beta$ -epoxide (i.e., the compound of formula (VI)) as white crystals; m.p. 188.5-191.5°C. FTIR (KBr, diffuse reflectance):  $\gamma_{\max}$  3510 (OH), 2947, 2887, 2669, 1649, 1469, 1438, 1369, 1326, 1220, 1186, 1132, 1109, 1084, 1066, 1047, 1004; NMR (CDCl<sub>3</sub>)  $\delta$  0.77(s, 18-CH<sub>3</sub>), 1.35(s, 21-CH<sub>3</sub>), 6.04 (m, C-11 H of  $\alpha$ -epoxide);  
15 MS (EI) m/z (relative intensity) 418 (M<sup>+</sup>, 18), 400 (M<sup>+</sup>-H<sub>2</sub>O, 77), 293 (35), 141 (30), 131 (92), 115 (56), 87 (100). Anal. calc'd for C<sub>24</sub>H<sub>34</sub>O<sub>6</sub>: C, 68.88; H, 8.19  
20 Found: C, 68.70; H, 8.09.

## EXAMPLE 5

25 The Preparation of the Compound of Formula (VII) (3,20-bis-Ethylenedioxy-5 $\alpha$ ,17 $\alpha$ -dihydroxy-11 $\beta$ -(4-N,N-dimethylaminophenyl)-19-norpregn-9-ene) from the Compound of Formula (VI)

30 A dry 12-L, 3-neck flask equipped with a stir shaft, condenser, and argon inlet, was charged with 51.1 g of activated magnesium (2.10 mol). Several crystals of iodine and 1.0 mL of dibromoethane were added, followed by the addition of 1,000 mL of THF. While  
35 maintaining stirring, 2,000 mL of a THF solution containing 421.7 g of p-bromo-N,N-dimethylaniline (2.11 mol) were added at such a rate that a gentle reflux was maintained. Upon completion of the addition, the mixture was stirred for 1.5 hours and cooled to room

temperature. 20.8 g of copper (I) chloride (0.21 mol) were added and stirred at room temperature for 30 minutes. 1,500 mL of a THF solution containing 176.3 g of the 9,11-unsaturated 5 $\alpha$ ,10 $\beta$ -epoxide of formula (VI) (0.42 mol) were added over 30 minutes. After stirring for 1 hour, the reaction was quenched with the slow addition of an ammonium chloride solution (approx. 800 g NH<sub>4</sub>Cl/approx. 4,500 mL total volume) and stirred for 30 minutes. While stirring vigorously, air was bubbled through the mixture for 5-10 minutes to oxidize Cu<sup>I</sup> to Cu<sup>II</sup>. The layers were allowed to separate. The upper THF layer was washed with 1,000 mL of 10% ammonium chloride solution. The THF layer was diluted with 4,500 mL of ether and washed with 10% by weight ammonium chloride (5 x 1,000 mL) and 2.0 N ammonium hydroxide (5 x 1,000 mL). The THF/ether solution was washed with water and brine. After drying over sodium sulfate, the solvent was evaporated in vacuo. The residue obtained was diluted with ether, and the solid was collected by filtration, washed with ether, and dried in vacuo to give 179.7 g of the compound of formula (VII) in 79% yield as white crystals; mp = 236°-240°C dec. Extraction of all aqueous washes with ether gave an additional 6.8 g of the compound of formula (VII). A total of 186.5 g of the desired compound (VII) was obtained in 82% yield. FTIR (KBr, diffuse reflectance):  $\gamma_{\max}$  3573, 3543, 3087, 2976, 2945, 2874, 1612, 1516, 1484, 1447, 1484, 1396, 1371, 1340, 1238, 1214, 1128, 1190, 1100, 1076, 1052; NMR (CDCl<sub>3</sub>)  $\delta$  0.49 (s, 18-CH<sub>3</sub>), 1.39 (s, 21-CH<sub>3</sub>), 3.92 (br.m, 3,20-diketal), 4.20 (d, C-11 H), 6.70 and 7.16 (d, aromatic H); MS (EI) m/z (relative intensity): 539 (M<sup>+</sup>, 83), 521 (M<sup>+</sup> - H<sub>2</sub>O, 57), 324 (21), 238 (26), 134 (10), 121 (30), 87 (100). Anal. calc'd. for C<sub>32</sub>H<sub>45</sub>NO<sub>6</sub> C, 71.21; H, 8.40; N, 2.60. Found C, 71.29; H, 8.35; N, 2.74.

## EXAMPLE 6

The Preparation of the Compound of Formula (VIII)  
(11 $\beta$ -(4-N,N-Dimethylaminophenyl)-17 $\alpha$ -hydroxy-19-norpregn-4,9-diene-3,20-dione) from the Compound of  
Formula (VII)

Argon was bubbled for 10 minutes through 3,250 mL  
of a 10:1 mixture of absolute ethanol and 8.5 vol.%  
sulfuric acid solution. 178.6 g of the compound of  
formula (VII) (0.33 mol) were added as a solid. The  
mixture was stirred, heated to reflux, and maintained at  
that temperature for 40 minutes. The reaction mixture  
was cooled in an ice bath, and the acid was neutralized  
by adding saturated sodium bicarbonate solution. The  
mixture was filtered, and the filtrate was evaporated in  
vacuo. The resulting aqueous mixture was diluted with  
2,000 mL of water and extracted with methylene chloride.  
The methylene chloride extracts were washed with water  
and brine, combined, and dried over sodium sulfate.  
Evaporation of the solvent gave 161.8 g of the compound  
of formula (VIII). The material was taken up in 1,350  
mL of ether and set aside to crystallize. This  
procedure gave 128.3 g of the compound of formula (VIII)  
as an off-white solid in 90% yield, m.p.: softens at  
103°C, foams at 125-128 °C. FTIR (KBr, diffuse  
reflectance):  $\gamma_{\max}$  3448 (OH), 3074, 1709 (C=O), 1643,  
1602 (conjugated-C=O), 1560, 1519, 1440; NMR (CDCl<sub>3</sub>)  $\delta$   
0.44 (s, 18-CH<sub>3</sub>), 2.24 (s, 21-CH<sub>3</sub>), 2.90 (s, -N(CH<sub>3</sub>)<sub>2</sub>),  
4.38 (d, C-11 H), 5.78 (br. s, C-4 H), 6.67 and 7.02  
(d, aromatic H); MS EI m/z (relative intensity) 433 (M<sup>+</sup>,  
35), 280(7), 134(21), 121(100). Anal. calc'd. for  
C<sub>28</sub>H<sub>35</sub>NO<sub>3</sub>: C, 77.56; H, 8.14; N, 3.23. Found C, 77.54; H,  
7.98; N, 3.46.



## EXAMPLE 7

The Preparation of the Compound of Formula (I)  
(17 $\alpha$ -Acetoxy-11 $\beta$ -(4-N,N-dimethylaminophenyl)-19-  
5 norpregna-4,9-diene-3,20-dione) From the Compound of  
Formula (VIII)

340 mL of acetic acid (5.92 mol) were added to a  
well stirred mixture containing 834 mL of  
10 trifluoroacetic anhydride (5.92 mol) in 2,300 mL of  
methylene chloride under argon. After stirring for 30  
minutes at room temperature, 51.3 g of p-toluenesulfonic  
acid (0.26 mol) were added, and the mixture was chilled  
to 0°C. 400 mL of a chilled (0°C) methylene chloride  
15 solution containing 128.3 g of the compound of formula  
(VIII) (0.30 mol) were added, and the reaction mixture  
was stirred at 0°C for 30 minutes. The reaction mixture  
was quenched with the cautious addition of a 4.5 N  
potassium carbonate solution until the pH was in the  
20 range of 7.0 - 7.5. The reaction mixture was diluted  
with water and extracted with methylene chloride. The  
methylene chloride extracts were washed with water and  
brine, combined, and dried over sodium sulfate.  
Evaporation of the solvent gave the acetate of formula  
25 (I) as a thick syrup.

The above syrup was dissolved in 300 mL of  
isopropyl alcohol and evaporated. The dissolution and  
evaporation were repeated three times. Finally, the  
remaining solid, which retained isopropyl alcohol as  
30 solvent of recrystallization, was dissolved in ethyl  
acetate and evaporated to give a stable foam. The foam  
was quickly dissolved in ether, and this solution was  
set aside to crystallize. The solid that formed was  
collected by filtration, washed with ether, and dried in  
35 vacuo to yield 105.7 g of the compound of formula (I) as  
yellow crystals in 75% yield; m.p. 183 - 185°C. FTIR  
(KBr, diffuse reflectance):  $\gamma_{\max}$  2945, 1735 and  
1714 (-C=O), 1664 and 1661 (conjugated -C=O), 1563, 1518,  
1441, 1351, 1305, 1252, 1203, 1171; NMR (CDCl<sub>3</sub>)  $\delta$  0.38


(s, 18-CH<sub>3</sub>), 2.10 (s, 17-OAc), 2.14 (s, 21-CH<sub>3</sub>), 2.92 (s, -N(CH<sub>3</sub>)<sub>2</sub>, 4.44 (d, C-11 H), 5.83 (br. s, C-4 H), 6.71 and 7.07 (d, aromatic H); MS(EI) m/z (relative intensity) 475(M<sup>+</sup>, 41), 134(18), 121 (100). Analysis calculated for C<sub>30</sub>H<sub>37</sub>NO<sub>4</sub>: C, 75.76; H, 7.84; N, 2.94. Found: C, 75.80; H, 7.96; N, 3.09.

All of the references cited herein, including patents, patent applications, and publications, are hereby incorporated in their entireties by reference.

While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.


## WHAT IS CLAIMED IS:

1. A method for preparing the compound of formula I




comprising

protecting the hydroxyl group in the compound of formula II




with protecting group B which comprises a halomethyl functional group to provide the compound of formula III



reacting the protect d c mpound of formula III with an alkali or alkaline earth metal anion radical comprised of an alkali or alkaline earth metal and an


and a radical and hydrolyzing the resulting compound to provide the compound of formula IV



(IV),

5


ketalizing the carbonyl groups of the compound of formula IV to provide the compound of formula V



(V),

10

epoxidizing the compound of formula V to provide the 9,11-unsaturated 5α,10β-epoxide of formula VI




(VI),

15

opening the epoxide ring of the compound of formula VI and introducing into the axial position of C<sub>11</sub> a N,N-dimethylamino-phenyl functional group to provide the compound of formula VII


5



(VII),

10

deketalizing and dehydrating the compound of formula VII to provide the compound of formula VIII




(VIII),

15

and


acetylating the compound of formula VIII to provide the compound of formula I.

2. A method for preparing a crystalline form of the compound of formula VI



(VI)

comprising epoxidizing the compound of formula V




(V)

with an adduct formed from the reaction of a hexahalogenated acetone and a peroxide in the presence of an inorganic phosphate to provide a crystalline form of the compound of formula VI having a melting point of 188.5°C to 191.5°C.

3. The method according to claim 2, wherein the inorganic phosphate is anhydrous disodium phosphate and the hexahalogenated acetone is hexafluoroacetone.

4. The method of claim 2, further comprising conjugate ring opening of the 5 $\alpha$ ,10 $\beta$  epoxide ring and introducing a N,N-dimethylaminophenyl functional group in the C<sub>11</sub> axial position by reacting a Grignard reagent prepared from a N,N-dimethylaniline and magnesium in the

presenc of a cuprous halide to provide the compound of formula VII



(VII).


5. The method of claim 4, wherein the cuprous halide is provided in less than an equimolar amount as compared to the epoxide.

6. The method of claim 5, wherein the Grignard reagent is prepared from the reaction of p-bromo-N,N-dimethylaniline and magnesium in the presence of a cuprous halide.

7. The method of claim 6, wherein the Grignard reagent is provided in a molar amount which is no greater than about five times the molar amount of the epoxide.

8. The method of claim 4, further comprising forming a crystalline form of the compound of formula VII having a melting point of 236°C to 240°C.


9. The method of claim 8, further comprising deketalizing and dehydrating the compound of formula VII to provide the compound of formula VIII.



(VIII).

10. The method of claim 9, further comprising forming a crystalline form of the compound of formula VIII which softens at 103°C and foams at 125° to 128°C.

11. The method of claim 10, further comprising reacting the compound of formula VIII with an acetylating agent to provide the compound of formula I.




(I).

12. The method of claim 11, further comprising forming a crystalline form of the compound of formula I which has a melting point of 183°C to 185°C.


13. The method according to claim 12, wherein the acetylating agent is a mixture prepared from trifluoroacetic anhydride and acetic acid.



14. The method according to claim 2, wherein the compound of formula V is prepared by protecting the hydroxyl group in the compound of formula II




with chloromethyldimethylchlorosilane to provide the compound of formula IIIa



forming a crystalline form of the compound of formula IIIa having a melting point of 80°C and 82°C,


reacting the compound of formula IIIa with an alkali metal anion radical of 4,4'-di-tert-butylbiphenyl and hydrolyzing the ketal to provide the compound of formula IV



and

ketalizing the carbonyl groups of the compound of formula IV to provide the compound of formula V


5



(V).

15. A method for preparing the compound of formula I

10




(I),

comprising

15


(a) deketalizing and dehydrating the compound of formula VII



(VII),

20

to form the compound of formula VIII




(VIII),

5

(b) isolating the compound of formula VIII formed in step (a), and

(c) acetylating the compound of formula VIII isolated in step (b) to provide the compound of

10 formula I




(I).

15

16. The method according to claim 15, wherein the isolation of step (b) is completed by crystallizing the compound of formula VIII.

17. A crystalline form of the compound of formula  
IIIa




(IIIa),

5

having a melting point of 80°C to 82°C.


18. A crystalline form of the compound of  
10 formula VI



(VI),

15 having a melting point of 188.5°C to 191.5°C.

19. A crystalline form of the compound of formula VII




(VII),

5

having a melting point of 236°C to 240°C.


20. A crystalline form of the compound of  
10 formula VIII



(VIII),

15 which softens at 103°C and foams at 125°C to 128°C.

21. A crystalline form of the compound of formula I



(I),

5

which has a melting point of 183°C to 185°C.





FIG. 1

2/4

**FIG. 1**  
(CONTINUED)



3/4





FIG. 2

4/4



- A)  $\text{ClSi}(\text{Me})_2\text{CH}_2\text{Cl}$ ,  $\text{Et}_3\text{N}$ , DMAP, THF  
 B) 4,4'-di-tert-butylbiphenyl (DBB), Li, THF,  $-75$  to  $-30^\circ\text{C}$   
 C)  $\text{HOCH}_2\text{CH}_2\text{OH}$ ,  $(\text{EtO})_3\text{CH}$ , p-TsOH,  $\text{CH}_2\text{Cl}_2$   
 D)  $(\text{CF}_3)_2\text{CO} \cdot 3 \text{H}_2\text{O}$ , 30%  $\text{H}_2\text{O}_2$ ,  $\text{CH}_2\text{Cl}_2$ ,  $4^\circ\text{C}$   
 E) p-bromo-N,N-dimethylaniline, Mg, CuCl, THF  
 F)  $\text{H}_2\text{SO}_4 / \text{H}_2\text{O} / \text{EtOH}$ , reflux  
 G)  $(\text{CF}_3\text{CO})_2\text{O}$ , HOAc, TsOH,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$

**FIG. 2**  
 (CONTINUED)